US 12,227,547 B2
Modulators of CAS9 polypeptides and methods of use thereof
Jennifer A. Doudna, Berkeley, CA (US); Kyle E. Watters, Moraga, CA (US); Haridha Shivram, Berkeley, CA (US); and Christof Fellmann, Berkeley, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/270,691
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Sep. 9, 2019, PCT No. PCT/US2019/050214
§ 371(c)(1), (2) Date Feb. 23, 2021,
PCT Pub. No. WO2020/055748, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/729,295, filed on Sep. 10, 2018.
Prior Publication US 2021/0340199 A1, Nov. 4, 2021
Int. Cl. C07K 14/47 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01)
CPC C07K 14/4703 (2013.01) [C12N 9/22 (2013.01); C12N 15/1137 (2013.01); C07K 2319/09 (2013.01); C07K 2319/40 (2013.01); C12Y 301/00 (2013.01)] 22 Claims
 
1. A fusion polypeptide comprising:
a) anti-CRISPR (Acr) polypeptide that is an inhibitor of an enzymatic activity of a Cas9 polypeptide, wherein the Acr polypeptide comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 12; and
b) a heterologous fusion partner.